Effector Therapeutics Inc (EFTR) — Net Asset Quality Index
Effector Therapeutics Inc (EFTR) has a Net Asset Quality Index of 3.0% as of March 2024. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $27.13 Million minus total liabilities of $26.30 Million yields net assets of $827.00K. A higher index indicates a stronger, lower-leverage balance sheet. See EFTR defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Effector Therapeutics Inc Net Asset Quality Index Over Time (2019–2023)
This chart shows how Effector Therapeutics Inc's Net Asset Quality Index has evolved across 5 annual periods from 2019 to 2023. As of March 2024, the index stands at 3.0%, representing net assets of $827.00K against total assets of $27.13 Million USD. Explore cash efficiency ratio of Effector Therapeutics Inc to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Effector Therapeutics Inc (2019–2023)
The table below presents the year-by-year Net Asset Quality Index for Effector Therapeutics Inc from 2019 to 2023, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Effector Therapeutics Inc stock valuation.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2023 | -28.2% | $-5.79 Million | $20.54 Million | $26.34 Million | ▼ -41.6 pp |
| 2022 | 13.4% | $3.90 Million | $29.08 Million | $25.18 Million | ▼ -18.6 pp |
| 2021 | 32.0% | $17.28 Million | $54.06 Million | $36.77 Million | ▲ +823.7 pp |
| 2020 | -791.7% | $-132.25 Million | $16.70 Million | $148.95 Million | ▼ -520.1 pp |
| 2019 | -271.6% | $-13.84 Million | $5.09 Million | $18.93 Million | — |